- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT01927198
RDEA3170 Monotherapy in Subjects With Gout
June 4, 2015 updated by: Ardea Biosciences, Inc.
A Phase 2, Randomized, Double-Blind, Multicenter, Placebo-Controlled Study to Evaluate the Efficacy and Safety of RDEA3170 Monotherapy in Subjects With Gout
This study will assess the serum uric acid lowering effects and safety of 3 dose levels of RDEA3170 compared to placebo in subjects with gout.
Study Overview
Status
Completed
Conditions
Intervention / Treatment
Detailed Description
This monotherapy study is the initial Phase 2 study for RDEA3170 and is designed to compare the safety and efficacy of multiple dose levels of RDEA3170 with placebo when given for up to 24 weeks to subjects with gout.
The placebo control for RDEA3170 is included in this study to minimize bias in study assessments and monitoring.
Further, to accomplish the goal of understanding the safety profile of RDEA3170, it is important to compare RDEA3170 monotherapy with placebo for at least 24 weeks.
Study Type
Interventional
Enrollment (Actual)
172
Phase
- Phase 2
Contacts and Locations
This section provides the contact details for those conducting the study, and information on where this study is being conducted.
Study Locations
-
-
Alabama
-
Birmingham, Alabama, United States, 35235
-
Gulf Shores, Alabama, United States, 36542
-
Mobile, Alabama, United States, 36608
-
-
Arizona
-
Glendale, Arizona, United States, 85308
-
Peoria, Arizona, United States, 85381
-
Tucson, Arizona, United States, 85704
-
-
California
-
Anaheim, California, United States, 92805
-
Gold River, California, United States, 95670
-
Irvine, California, United States, 92618
-
San Leandro, California, United States, 94578
-
San Ramon, California, United States, 94582
-
-
Colorado
-
Colorado Springs, Colorado, United States, 80918
-
Denver, Colorado, United States, 80220
-
-
Florida
-
Jacksonville, Florida, United States, 32205
-
Pembroke Pines, Florida, United States, 33027
-
Tampa, Florida, United States, 33606
-
Winter Haven, Florida, United States, 33880
-
-
Georgia
-
Dunwoody, Georgia, United States, 30338
-
-
Hawaii
-
Honolulu, Hawaii, United States, 96814
-
-
Idaho
-
Meridian, Idaho, United States, 83646
-
-
Illinois
-
Gurnee, Illinois, United States, 60031
-
-
Kentucky
-
Elizabethtown, Kentucky, United States, 42701
-
Lexington, Kentucky, United States, 40503
-
-
Louisiana
-
Metairie, Louisiana, United States, 70006
-
-
Mississippi
-
Jackson, Mississippi, United States, 39202
-
-
Nevada
-
Reno, Nevada, United States, 89502
-
-
New York
-
New York, New York, United States, 10016
-
-
North Carolina
-
Charlotte, North Carolina, United States, 28210
-
Hickory, North Carolina, United States, 28602
-
Shelby, North Carolina, United States, 28150
-
Shelby, North Carolina, United States, 28152
-
Wilmington, North Carolina, United States, 28401
-
Winston-Salem, North Carolina, United States, 27103
-
-
North Dakota
-
Fargo, North Dakota, United States, 58103
-
-
Ohio
-
Cincinnati, Ohio, United States, 45224
-
Perrysburg, Ohio, United States, 43551
-
Perrysburgh, Ohio, United States, 43551
-
Willoughby Hills, Ohio, United States, 44904
-
-
Pennsylvania
-
Altoona, Pennsylvania, United States, 16602
-
-
South Carolina
-
Greenville, South Carolina, United States, 29615
-
Greer, South Carolina, United States, 29651
-
Mount Pleasant, South Carolina, United States, 29464
-
Rock Hill, South Carolina, United States, 29732
-
Spartanburg, South Carolina, United States, 29303
-
-
Tennessee
-
Spring Hill, Tennessee, United States, 37174
-
-
Texas
-
Houston, Texas, United States, 77098
-
-
Utah
-
Bountiful, Utah, United States, 84010
-
-
Virginia
-
Midlothian, Virginia, United States, 23114
-
Richmond, Virginia, United States, 23219
-
Virginia Beach, Virginia, United States, 23462
-
-
Participation Criteria
Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.
Eligibility Criteria
Ages Eligible for Study
18 years to 70 years (Adult, Older Adult)
Accepts Healthy Volunteers
No
Genders Eligible for Study
All
Description
Inclusion Criteria:
- Subject meets the diagnosis of gout per the American Rheumatism Association Criteria for the Classification of Acute Arthritis of Primary Gout.
- Subject has a serum urate level ≥ 6.5 mg/dL and ≤ 10.0 mg/dL during the Screening Period.
- Subject has a body mass index < 40 kg/m2.
Exclusion Criteria:
- Subject is pregnant or breastfeeding. Subject consumes more than 14 drinks of alcohol per week (eg, 1 drink = 5 oz [150 mL] of wine, 12 oz [360 mL] of beer, or 1.5 oz [45 mL] of hard liquor).
- Subject has a history or suspicion of kidney stones.
- Subject has a history or suspicion of drug abuse within the past 5 years.
- Subject has a history of symptomatic myositis/myopathy or rhabdomyolysis.
- Subject has a known or suspected human immunodeficiency virus infection.
- Subject has a positive test for active hepatitis B or hepatitis C infection.
- Subject has a history of malignancy within the previous 5 years with the exception of non-melanoma skin cancer that has been treated with no evidence of recurrence, treated cervical dysplasia, or treated in situ Grade 1 cervical cancer.
- Subject within the last 12 months with: unstable angina, New York Heart Association class III or IV heart failure, myocardial infarction, stroke, or deep venous thrombosis; or subjects currently receiving anticoagulants.
- Subject has a QT interval corrected for heart rate according to Fridericia's formula > 450 msec during the Screening Period, confirmed by a repeat assessment.
- Subject has uncontrolled hypertension.
- Subject has an estimated creatinine clearance < 60 mL/min.
- Subject has an alkaline phosphatase > 2.0 x upper limit of normal during the Screening Period.
- Subject has active liver disease or impaired hepatic function.
- Subject is receiving chronic treatment with more than 325 mg salicylates per day.
- Subject has a medical condition that requires or may require systemic immunosuppressive (eg, chronic low-dose oral prednisone) or immunomodulatory treatment.
- Subject is unable to take colchicine for gout flare prophylaxis.
- Subject is receiving strong or moderate CYP3A inhibitors, p-glycoprotein inhibitors, or digoxin.
- Subject received any strong enzyme- inducing drug or product (eg, rifampin, rifabutin, phenytoin, phenobarbital, St. John's Wort) within 2 months prior to Day 1 or refuses to refrain from taking these medications until the end of the study.
- Subject received an investigational therapy within 30 days or 5 half-lives (whichever is longer) prior to the Screening Period.
- Subject has any other medical or psychological condition, which in the opinion of the Investigator and/or Medical Monitor, might create undue risk to the subject or interfere with the subject's ability to comply with the protocol requirements, or to complete the study.
Study Plan
This section provides details of the study plan, including how the study is designed and what the study is measuring.
How is the study designed?
Design Details
- Primary Purpose: Treatment
- Allocation: Randomized
- Interventional Model: Parallel Assignment
- Masking: Double
Arms and Interventions
Participant Group / Arm |
Intervention / Treatment |
---|---|
Placebo Comparator: Placebo
Placebo group
|
|
Experimental: RDEA3170 5 mg qd
No titration.
|
|
Experimental: RDEA3170 10 mg qd
Increase from RDEA3170 5 mg to RDEA3170 10 mg qd at Week 2.
|
|
Experimental: RDEA3170 12.5 mg qd
Increase from RDEA3170 10 mg to RDEA3170 12.5 mg qd at Week 4.
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Efficacy of RDEA3170 monotherapy at Week 12
Time Frame: Week 12
|
Percent change from baseline in serum urate levels at Week 12.
|
Week 12
|
Secondary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Incidence of treatment-emergent adverse events and change from baseline in laboratory values, vital signs, and electrocardiograms
Time Frame: 8 months
|
Safety assessments include adverse event (AE) recording, gout flare recording, clinical safety laboratory tests (eg, hematology, serum chemistry, and urinalysis), physical examinations, vital sign measurements, and ECGs.
|
8 months
|
Efficacy of RDEA3170 monotherapy at Week 24
Time Frame: Week 24
|
Percent change from baseline in serum urate levels at each visit.
Proportion of subjects with a serum urate level < 6.0 and < 5.0 mg/dL at each visit.
|
Week 24
|
Collaborators and Investigators
This is where you will find people and organizations involved with this study.
Sponsor
Investigators
- Study Director: J. Hall, MD, Ardea Biosciences, Inc.
Study record dates
These dates track the progress of study record and summary results submissions to ClinicalTrials.gov. Study records and reported results are reviewed by the National Library of Medicine (NLM) to make sure they meet specific quality control standards before being posted on the public website.
Study Major Dates
Study Start
August 1, 2013
Primary Completion (Actual)
May 1, 2014
Study Completion (Actual)
July 1, 2014
Study Registration Dates
First Submitted
August 20, 2013
First Submitted That Met QC Criteria
August 20, 2013
First Posted (Estimate)
August 22, 2013
Study Record Updates
Last Update Posted (Estimate)
July 1, 2015
Last Update Submitted That Met QC Criteria
June 4, 2015
Last Verified
June 1, 2015
More Information
Terms related to this study
Additional Relevant MeSH Terms
Other Study ID Numbers
- RDEA3170-201
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Gout
-
Ai PengRecruitingGout Flare | Intercritical Gout | Advanced Gout | Asymptomatic HyperuricemiaChina
-
AmgenCompletedUncontrolled Gout | Chronic GoutUnited States
-
Sheffield Hallam UniversityCherry Research CommitteeUnknown
-
Olatec Therapeutics LLCRecruitingArthritis | Joint Pain | Gout | Gout Flare | Gouty Arthritis | Acute Gout Flare | Gout AttackUnited States, Spain, France
-
GeneScience Pharmaceuticals Co., Ltd.Huashan HospitalNot yet recruitingAcute Gout | Gout Initiating Urico-lowering TherapyChina
-
GeneScience Pharmaceuticals Co., Ltd.Huashan HospitalRecruitingGout Flare | Acute GoutChina
-
AmgenCompletedGout | Chronic Uncontrolled Gout | Uncontrolled GoutUnited States
-
Jiangsu HengRui Medicine Co., Ltd.Not yet recruitingPrimary Gout With Hyperuricemia in Adults
-
Jiangsu HengRui Medicine Co., Ltd.Not yet recruitingPrimary Gout and Hyperuricemia
-
Guangdong Provincial Hospital of Traditional Chinese...RecruitingAcute Pain | Acupuncture | Acute Gout ArthritisChina
Clinical Trials on Placebo
-
SamA Pharmaceutical Co., LtdUnknownAcute Bronchitis | Acute Upper Respiratory Tract InfectionKorea, Republic of
-
National Institute on Drug Abuse (NIDA)CompletedCannabis UseUnited States
-
AstraZenecaParexel; Spandauer Damm 130; 14050; Berlin, GermanyCompletedMale Subjects With Type II Diabetes (T2DM)Germany
-
Heptares Therapeutics LimitedCompletedPharmacokinetics | Safety IssuesUnited Kingdom
-
GlaxoSmithKlineCompletedPulmonary Disease, Chronic ObstructiveUnited Kingdom, Netherlands
-
ItalfarmacoCompletedBecker Muscular DystrophyNetherlands, Italy
-
Shijiazhuang Yiling Pharmaceutical Co. LtdXuanwu Hospital, BeijingCompleted
-
GlaxoSmithKlineCompletedInfections, BacterialUnited States
-
West Penn Allegheny Health SystemCompletedAsthma | Allergic RhinitisUnited States